Literature DB >> 7830275

Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.

B O Buckman1, T A Bonasera, K S Kirschbaum, M J Welch, J A Katzenellenbogen.   

Abstract

We describe the synthesis and tissue biodistribution of two 21-[fluoro-18F]progestin 16 alpha, 17 alpha-furanyl ketals, potential agents for imaging progesterone receptor (PR)-positive breast tumors in humans, using positron emission tomography. 21-Fluro-16 alpha, 17 alpha-[(R)-(1'-alpha-furylmethylidene)dioxy]-19- norpregn-4-ene-3,20-dione (endo-10a) and 21-fluoro-16 alpha, 17 alpha-[(R)-(1'-alpha-furylethylidene)dioxy]-19- norpregn-4-ene-3,20-dione (endo-10b) were chosen for radiochemical synthesis from a series of seven novel progestin 16 alpha, 17 alpha-(furanyldioxolanes) on the basis of their high relative binding affinity to PR (190% and 173%, respectively, relative to R5020 = 100%), their low nonspecific binding (NSB) (log P o/w = 3.87 and 4.13, respectively), and their resulting high binding selectivity indices (BSI; i.e., the ratio of their PR binding affinity to nonspecific binding). Radiochemical synthesis of these two species in high radiochemical purity and at high effective specific activity was accomplished by treatment of the corresponding diastereomerically pure 21-trifluoromethanesulfonates with fluorine-18 anion. In tissue biodistribution studies in estrogen-primed immature female Sprague-Dawley rats, both [18F]-endo-10a and [18F]endo-10b demonstrated high PR-selective uptake in the principal target tissues, the uterus and the ovaries, and relatively low uptake in fat and bone. The metabolism at the 21-position in these progestins (as monitored by in vivo defluorination) appears to be less than that in other 21-fluoroprogestins; this may reflect steric inhibition of metabolism at this site due to the bulk of the furan-substituted dioxolane ring at the 16 alpha, 17 alpha-position. Comparison with other fluorine-18-labeled progestins shows that the PR-specific uptake in uterine tissue correlates with the BSI of the ligand and that the fat uptake correlates with the NSB of the ligand at high levels of statistical significance. These two dioxolanes may prove to be useful as breast tumor-imaging agents in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7830275     DOI: 10.1021/jm00002a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.

Authors:  Amy M Fowler; Szeman Ruby Chan; Terry L Sharp; Nicole M Fettig; Dong Zhou; Carmen S Dence; Kathryn E Carlson; M Jeyakumar; John A Katzenellenbogen; Robert D Schreiber; Michael J Welch
Journal:  J Nucl Med       Date:  2012-06-05       Impact factor: 10.057

Review 2.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

3.  Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.

Authors:  Dong Zhou; Terry L Sharp; Nicole M Fettig; Hsiaoju Lee; Jason S Lewis; John A Katzenellenbogen; Michael J Welch
Journal:  Nucl Med Biol       Date:  2008-06-30       Impact factor: 2.408

4.  Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.

Authors:  Hai-Bing Zhou; Jae Hak Lee; Christopher G Mayne; Kathryn E Carlson; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

5.  Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.

Authors:  Dong Zhou; Mai Lin; Norio Yasui; Mohammed H Al-Qahtani; Carmen S Dence; Sally Schwarz; John A Katzenellenbogen
Journal:  J Labelled Comp Radiopharm       Date:  2014-02-17       Impact factor: 1.921

6.  Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.

Authors:  Szeman Ruby Chan; Amy M Fowler; Julie A Allen; Dong Zhou; Carmen S Dence; Terry L Sharp; Nicole M Fettig; Farrokh Dehdashti; John A Katzenellenbogen
Journal:  Clin Cancer Res       Date:  2014-12-17       Impact factor: 12.531

7.  Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione.

Authors:  Farrokh Dehdashti; Richard Laforest; Feng Gao; Rebecca L Aft; Carmen S Dence; Dong Zhou; Kooresh I Shoghi; Barry A Siegel; John A Katzenellenbogen; Michael J Welch
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

8.  Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.

Authors:  Kelley Salem; Manoj Kumar; Kyle C Kloepping; Ciara J Michel; Yongjun Yan; Amy M Fowler
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

Review 9.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 10.  Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer.

Authors:  Amy M Fowler; Amy S Clark; John A Katzenellenbogen; Hannah M Linden; Farrokh Dehdashti
Journal:  J Nucl Med       Date:  2016-02       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.